radiopharmaceuticals

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.